Gilead's Trodelvy Secures EU Nod for First-Line Metastatic TNBC Across PD-L1 Status
Event summary
- European Commission approves Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) for first-line metastatic triple-negative breast cancer (TNBC) with PD-L1 CPS ≥10.
- Approval based on Phase 3 ASCENT-04/KEYNOTE-D19 study showing 35% reduced risk of disease progression or death in PD-L1-positive metastatic TNBC.
- Trodelvy now established as backbone therapy for first-line metastatic TNBC across PD-L1 status in Europe.
- More than 75,000 breast cancer patients treated with Trodelvy globally since 2020.
The big picture
The European Commission's approval of Trodelvy in combination with Keytruda for first-line metastatic TNBC marks a significant stride in oncology treatment, addressing a critical unmet need for patients with this aggressive form of breast cancer. This approval solidifies Trodelvy's role as a backbone therapy, potentially reshaping the treatment paradigm for TNBC. Gilead's strategic focus on expanding Trodelvy's indications across various cancer types underscores its commitment to innovation in the oncology space.
What we're watching
- Market Penetration
- How Gilead will leverage this approval to expand Trodelvy's market share in first-line metastatic TNBC across Europe.
- Clinical Development
- The pace at which Gilead advances Trodelvy in ongoing Phase 3 trials across other high Trop-2 expression tumor types.
- Competitive Dynamics
- Whether this approval strengthens Gilead's position against competitors in the TNBC treatment landscape.